Welcome to the WCN 2021 Interactive Program
The congress will officially run on Central European Time (CET) - Rome Time
To convert the congress times to your local time Click Here
Please note that all sessions will run at their scheduled time and be followed by a LIVE Q&A/Discussion at the end
The viewing of sessions, cannot be accessed from this conference calendar. All sessions are accessible via the Virtual Platform
Sponsored Symposium
Session Time
14:00 - 14:30
Room
Industry 1
Chair(s)
- Piero Barbanti (Italy)
Session Description
Practical Approaches to Managing Migraine
Learning from clinicians, the practical approaches they take in managing migraine.
Learning from clinicians, the practical approaches they take in managing migraine.
Sponsored Symposium
Practical Approaches to Managing Migraine
Session Type
Sponsored Symposium
Session Name
Date
05.10.2021, Tuesday
Session Time
14:00 - 14:30
Room
Industry 1
Lecture Time
14:00 - 14:00
Sponsored Symposium
Supported by Eli Lilly
Session Type
Sponsored Symposium
Session Name
Date
05.10.2021, Tuesday
Session Time
14:00 - 14:30
Room
Industry 1
Lecture Time
14:00 - 14:00
Sponsored Symposium
Introduction
Session Type
Sponsored Symposium
Session Name
Date
05.10.2021, Tuesday
Session Time
14:00 - 14:30
Room
Industry 1
Lecture Time
14:00 - 14:05
Presenter
- Piero Barbanti (Italy)
Sponsored Symposium
Do you see that a certain patient profile is more appropriate for mAbs? In your practice, have you recognized any common characteristics that predicts better response?
Session Type
Sponsored Symposium
Session Name
Date
05.10.2021, Tuesday
Session Time
14:00 - 14:30
Room
Industry 1
Lecture Time
14:05 - 14:10
Presenter
- Dawn Buse (United States of America)
Sponsored Symposium
At what point during your patient’s medical journey do you prescribe mAbs to treat the patient’s migraine?
Session Type
Sponsored Symposium
Session Name
Date
05.10.2021, Tuesday
Session Time
14:00 - 14:30
Room
Industry 1
Lecture Time
14:10 - 14:15
Presenter
- Shuu-Jiun Wang (Taiwan)
Sponsored Symposium
When starting patients on CGRP mAb therapy, when do you observe the first benefits after starting the therapy? For how long do you treat those not initially responding, and when do you stop in those responding? And what happens in patient when you stop? Is there any wearing off with mAbs?
Session Type
Sponsored Symposium
Session Name
Date
05.10.2021, Tuesday
Session Time
14:00 - 14:30
Room
Industry 1
Lecture Time
14:15 - 14:20
Presenter
- Piero Barbanti (Italy)
Sponsored Symposium
Q&A
Session Type
Sponsored Symposium
Session Name
Date
05.10.2021, Tuesday
Session Time
14:00 - 14:30
Room
Industry 1
Lecture Time
14:20 - 14:30
Presenter
- Piero Barbanti (Italy)
- Dawn Buse (United States of America)
- Shuu-Jiun Wang (Taiwan)